N. Gilchrist
University of Toronto
19 Papers
53 Citations
N. Gilchrist is an academic researcher from University of Toronto. The author has contributed to research in topics: Osteoporosis & Denosumab. The author has an hindex of 8, co-authored 17 publications.
Chat about Author
Papers
Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension
Steven R. Cummings,Serge Ferrari,Richard Eastell,N. Gilchrist,Jens-Erik Beck Jensen,Michael R. McClung,Christian Roux,Ove Tørring,Ivo Valter,A. Wang,Jacques P. Brown +10 more
TL;DR: A majority of participants who sustained a vertebral fracture after discontinuing denosumab had multiple vertebral fractures, with greatest risk in participants with a prior vertebral break, therefore, patients who discontinue denosUMab should rapidly transition to an alternative antiresorptive treatment.
602
Development of the Asia pacific consortium on osteoporosis (APCO) framework: Clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-pacific region
Manju Chandran,P. J. Mitchell,T. Amphansap,Sanjay Kumar Bhadada,Manjeet Chadha,Ding-Cheng Chan,Yoon Sok Chung,Peter R. Ebeling,N. Gilchrist,A. Habib Khan,P. Halbout,Fen Lee Hew,H.-P. T. Lan,Tang Ching Lau,J. K. Lee,Sarath Lekamwasam,G. Lyubomirsky,Leilani B Mercado-Asis,Ambrish Mithal,Tuan V. Nguyen,D. Pandey,Ian R. Reid,Atsushi Suzuki,T. T. Chit,K. L. Tiu,T. Valleenukul,C. K. Yung,Y. L. Zhao +27 more
TL;DR: In this article, the authors conducted a structured comparative analysis of existing CPGs in the Asia-Pacific region using a 5IQ model (identification, investigation, information, intervention, integration, and quality).
Zoledronate in the prevention of Paget's (ZiPP) : protocol for a randomised trial of genetic testing and targeted zoledronic acid therapy to prevent SQSTM1-mediated Paget's disease of bone
Owen Cronin,Laura Forsyth,Kirsteen Goodman,Steff Lewis,Catriona Keerie,Allan Walker,Mary Porteous,Roseanne Cetnarskyj,Lakshminarayan R. Ranganath,Peter Selby,Geeta Hampson,Rama Chandra,Shu Ho,Jon H Tobias,Steven Young-Min,Malachi J. McKenna,Rachel K Crowley,William D. Fraser,Luigi Gennari,Ranuccio Nuti,Maria Luisa Brandi,Javier del Pino-Montes,Jean-Pierre Devogelaer,Anne Durnez,Giancarlo Isaia,Marco Di Stefano,Núria Guañabens,Josep Blanch,Markus J. Seibel,Markus J. Seibel,John P. Walsh,Mark A. Kotowicz,Geoffrey C. Nicholson,Emma L. Duncan,Emma L. Duncan,Emma L. Duncan,Gabor Major,Anne Horne,N. Gilchrist,Maarten Boers,Gordon D Murray,Keith Charnock,Diana Wilkinson,R. Graham G. Russell,Stuart H. Ralston +44 more
TL;DR: The Zoledronate in the Prevention of Paget’s disease trial (ZiPP) will determine if prophylactic therapy with the bisphosphonate zoledronic acid (ZA) can delay or prevent the development of PDB in people who carry SQSTM1 mutations.
28
Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial
S. Silverman,Hema N. Viswanathan,Y-C Yang,A. Wang,Steven Boonen,S Ragi-Eis,Patrice Fardellone,N. Gilchrist,Paul Lips,Michael C. Nevitt,S Palacios Gil-Antuñano,Karel Pavelka,Dennis A. Revicki,Jean-Pierre Simon,D. Macarios,Ethel S. Siris +15 more
TL;DR: Findings not only demonstrate that incident clinical fractures impact HRQoL but also contribute new information regarding the impact of these fracture events on HRZoL over time.
27
Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5 year results of a phase 2 trial
Heinrich Resch,Neil Binkley,Henry G. Bone,John A. Eisman,N. Gilchrist,Bente L. Langdahl,J. Rodriguez Portales,Andrew Denker,Antonio Lombardi,C. Le Bailly De Tilleghem,Carolyn DaSilva,Elizabeth Rosenberg,Albert Leung +12 more
9